Early response in cytokine and miR-124a, -125b, -223 expression to anti-CD20 in Multiple Sclerosis and its animal model – a preliminary analysis

Multiple Sclerosis (MS) is an autoimmune, demyelinating, inflammatory disorder. The anti-CD20 monoclonal antibody ocrelizumab targets B cells, effectively controlling the disease. MicroRNAs (miRNAs), small molecules modulating immune responses and neuroinflammation, may serve as biomarkers for disea...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2026-02, Vol.411, p.578823, Article 578823
Main Authors: Orefice, Nicola Salvatore, Amoriello, Roberta, Maghrebi, Olfa, Ballerini, Chiara, Baldi, Giovanni, Arpino, Roberta, Abate, Marianna, Zappavigna, Silvia, Pastò, Luisa, Amato, Maria Pia, Caraglia, Michele, Ballerini, Clara
Format: Article
Language:English
Subjects:
Adult
Animals
Anti-CD20 treatment
Antibodies, Monoclonal, Humanized - pharmacology
Antibodies, Monoclonal, Humanized - therapeutic use
Antigens, CD20 - immunology
Cytokines
Cytokines - biosynthesis
Cytokines - blood
Disease Models, Animal
EAE
Encephalomyelitis, Autoimmune, Experimental - drug therapy
Encephalomyelitis, Autoimmune, Experimental - immunology
Encephalomyelitis, Autoimmune, Experimental - metabolism
Female
Humans
Male
Mice
Mice, Inbred C57BL
microRNA
MicroRNAs - biosynthesis
Middle Aged
Multiple Sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - metabolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!